Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

April 3, 2018

Study Completion Date

April 3, 2018

Conditions

Non-Small Cell Lung CancerLeptomeningeal MetastasesBrain Metastases

Interventions

DRUG

Tesevatinib

Trial Locations (7)

Georgetown University Medical Center, Washington D.C.

Sarah Cannon Research Institute, Nashville

UT M.D. Anderson Cancer Center, Houston

University of Colorado Cancer Center, Aurora

Beverly Hills Cancer Center, Beverly Hills

John Wayne Cancer Institute, Santa Monica

USC Norris Oncology/Hematology Newport Beach, Newport Beach

All Listed Sponsors

lead

Kadmon Corporation, LLC

INDUSTRY

NCT02616393 - Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases | Biotech Hunter | Biotech Hunter